82 Spatial immunophenotyping of longitudinal metastatic melanoma specimens to identify biomarkers of response and resistance to combination anti-LAG-3 + anti-PD-1-based immunotherapies

Similar Items

• Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies
  by: Tuba N. Gide, et al.
  Published: (2023-12-01)
• Classification of the tumor immune microenvironment and associations with outcomes in patients with metastatic melanoma treated with immunotherapies
  by: Ines Pires da Silva, et al.
  Published: (2023-10-01)
• Stroma-infiltrating T cell spatiotypes define immunotherapy outcomes in adolescent and young adult patients with melanoma
  by: Xinyu Bai, et al.
  Published: (2024-04-01)
• Single-cell characterization of anti–LAG-3 and anti–PD-1 combination treatment in patients with melanoma
  by: Jani Huuhtanen, et al.
  Published: (2023-03-01)
• Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites
  by: John F Thompson, et al.
  Published: (2022-09-01)